JANX Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modu…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains? Iovance Biotherapeutics (IOVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. | ||
 Is Janux’s Dual JANX013–JANX007 Trial Advancing a Durable Precision Oncology Platform for JANX? Janux Therapeutics has recently dosed the first patient in its Phase 1 trial evaluating JANX013 in combination with JANX007 for metastatic castration-resistant prostate cancer, marking a new step in its clinical pipeline. This trial brings fresh attention to Janux Therapeutics’ prostate cancer platform, highlighting how the company is expanding its precision oncology approach into a difficult-to-treat setting. We’ll now examine how progress in this metastatic castration-resistant prostate... | ||
Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks Pricey Janux Therapeutics (JANX) just hit a clinical milestone, dosing the first patient in its Phase 1 trial of JANX013 with JANX007 for metastatic castration-resistant prostate cancer. This development is sharpening investor focus on this prostate cancer platform. The JANX share price has cooled in the near term, with a 1-month share price return down 9.6% and a 7-day move down 1.75%, even as the 90-day share price return is up 6.36% and the year-to-date share price return stands at 19.41%. Over a... | ||
 Chipotle downgraded, Darden upgraded: Wall Street's top analyst calls Chipotle downgraded, Darden upgraded: Wall Street's top analyst calls | ||
 Here Are Monday’s Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Domino’s Pizza, Fortune Brands, Golar LNG, Jersey Mike’s Subs, Roku, and More Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh initiations spanning pharma giants, fast-casual chains, and streaming players. Find out which names got bullish bets and which lost their analyst backing. | ||
 Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile In the past, Janux Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$21.97 million, or US$0.35 per share, compared with a net loss of US$33.86 million, or US$0.55 per share, a year earlier. For the first half of 2026, the company also reduced its net loss to US$46.33 million, or US$0.74 per share, signaling improving cost control and operating efficiency versus the prior-year period. We will now examine how Janux Therapeutics' reduced net loss and improving... | ||
 Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates Janux Therapeutics (JANX) delivered earnings and revenue surprises of -34.62% and -72.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership Most small-cap biotech stocks are pure clinical bets. These three already have revenue on the books and insiders backing them with their own capital. | ||